Introduction
============

Colorectal cancer (CRC) is the third most frequent type of cancer diagnosed and the second leading cause of cancer-related deaths in the United States, with an estimated 132,700 new diagnoses and 49,700 deaths in 2015 ([@b1-or-37-01-0057]). Approximately 25% of patients present with metastatic disease, while another 25--35% of patients develop metastatic disease during or after treatment, with the liver being the most common site of metastases ([@b2-or-37-01-0057]). Surgical resection has been shown to be the only potentially curative option for colon cancer metastasis to the liver ([@b3-or-37-01-0057]), resulting in a 25--40% overall survival at 5 years compared to 0--5% in those not having a liver resection. However, only about 15% of patients are considered to be resectable at presentation ([@b2-or-37-01-0057]). While improvements in chemotherapy regimens and increasingly aggressive surgical approaches have resulted in improvements in survival rates for metastatic patients ([@b4-or-37-01-0057]), patients with unresectable, chemo-refractory colorectal cancer liver metastases (CRCLM) have limited local treatment options. In addition to being prognostic for overall survival, the presence of hepatic disease is the major contributor to the cause of death in approximately half of the metastatic CRC patients ([@b5-or-37-01-0057]), indicating that local control of the liver is an important aspect of disease management and outcomes.

For unresectable liver metastases, local therapies include stereotactic body radiation therapy (SBRT), hepatic arterial infusion of chemotherapy, arterially directed embolic therapy, radiofrequency ablation, and liver directed radiation. Selection of these different modalities often depends on the extent, size, and location of the disease ([@b6-or-37-01-0057]). Yttrium-90 (^90^Y) radioembolization exploits the physiological difference in the blood flow between tumors and the normal liver to preferentially deliver radiation to the metastases, thereby shrinking the tumors while sparing the healthy liver ([@b7-or-37-01-0057]). Liver directed radiation has shown promising results in a variety of institutional studies, demonstrating promising survival outcomes and low toxicities ([@b8-or-37-01-0057]--[@b10-or-37-01-0057]). A recent randomized phase III trial, SIRFLOX, which compared first line chemotherapy vs. the same chemotherapy with selective internal radiation, demonstrated a significant delay of disease progression in the liver ([@b11-or-37-01-0057]).

CRC is a heterogeneous disease composed of multiple disease subtypes ([@b12-or-37-01-0057]). While about 25% of CRCs are associated with a family history, suggesting a role for inherited genetic mutations, only a small percentage of family historylinked cancers are associated with highly penetrant mutations in major genes. The majority of CRCs occur sporadically, developing in a multi-step process, involving an accumulation of mutations in tumor-suppressor genes and oncogenes ([@b13-or-37-01-0057]). Mutations in KRAS have been associated with 33--48% of CRCs. The KRAS protein is a downstream effector of EGFR receptor tyrosine kinase activity, which activates intracellular signaling cascades mediated by the RAF/MEK, MAPK, AKT and PI3K pathways ([@b14-or-37-01-0057]). Mutations in KRAS have been linked to CRC progression, with KRAS mutants having worse progression-free survival and overall survival compared to wild-type (WT) patients ([@b13-or-37-01-0057],[@b15-or-37-01-0057]--[@b17-or-37-01-0057]). The impact of KRAS mutation on radiation response is less clear, with one group reporting a greater survival benefit after ^90^Y radioembolization in WT vs. KRAS mutant patients. However, as there was no evaluation of local control after therapy, the differential assessment of radiation response in the two groups remains unclear ([@b18-or-37-01-0057]).

The presence of abnormally high levels of circulating cell-free DNA (ccfDNA) in the plasma of cancer patients has been well established and is thought to result from a variety of different mechanisms including apoptosis, necrosis, and circulating tumor cell lysis ([@b19-or-37-01-0057],[@b20-or-37-01-0057]). In CRC patients, an elevated plasma DNA concentration has been shown to be diagnostic for benign vs. malignant disease and to correlate with worse progression-free survival and overall survival after chemotherapy ([@b21-or-37-01-0057]--[@b23-or-37-01-0057]). DNA fragmentation index (FI), which is measured as the ratio of longer to shorter DNA fragments, has been shown to be higher in patients with advanced stages of breast cancer and with post-operative recurrence ([@b24-or-37-01-0057]). In addition, recently, the level of ccfDNA fragmentation has also been shown to correlate with survival in metastatic colon cancer patients ([@b22-or-37-01-0057]). However, changes in ccfDNA concentration and FI after ^90^Y radioembolization have not been assessed.

Here we report on our institutional experience on the efficacy of resin-based ^90^Y radioembolization for the treatment of CRCLM and the changes in ccfDNA levels and FI with liver directed internal radiation, investigating whether gene mutations in KRAS could serve as prognostic factors for ^90^Y treatment of CRCLM.

Materials and methods
=====================

### Patient selection

This retrospective review and prospective blood evaluation was approved by the Institutional Review Board (IRB 2008-344) of Georgetown University. From May 2011 to March 2015, a total of 58 patients underwent ^90^Y treatment for CRCLM at our institution. Patients eligible for study inclusion had histologically-confirmed CRC with liver metastases. Patients were included irrespective of prior treatment, including prior chemotherapy, surgery, or radiation therapy. All patients were not considered candidates for surgical resection and many of the patients were considered refractory to chemotherapy. Lesions were considered for treatment in any location within the liver. Patients generally were expected to have a life expectancy of at least 6 months and adequate hepatic function.

### Pre-treatment imaging, planning, and treatment

All patients underwent pre-procedural imaging with computed tomography (CT), FDG PET-CT, and/or MRI to determine liver tumor location, size, and volume. Three dimensional volumetric software was utilized to evaluate the total tumor volume, total liver volume, and total liver tumor burden (ratio of TV/LV). A pre-procedure planning angiogram and embolization of extrahepatic arteries at risk of nontarget perfusion of ^90^Y microspheres was performed. Hepatopulmonary shunt estimation was performed using Tc-99m-MAA, and this was judged to be adequate if \<20%. Therapy with ^90^Y microspheres was performed within 2 weeks of initial planning angiography. ^90^Y microsphere infusion followed the manufacturer\'s guidelines. Following delivery, a SPECT of the abdomen was performed to assess the distribution of the microspheres. The patients were discharged home the same day.

Depending on extent of disease within the liver at presentation, patients received either bilobar (right and left lobe) or unilobar treatment. For bilobar treatment, the first lobe treatment was followed by the second lobe treatment approximately 30 days later. Infusion of ^90^Y microspheres was performed by both the interventional radiologist and radiation oncologist. Patients were treated to a mean dose of 43.87 Gy and mean activity of 24.28 mCi.

### Plasma isolation, ccfDNA extraction, qPCR, and AFM preparation

Sample handling was in accordance with published NCI biospecimen best practices. A 10 ml sample of blood was collected in a K2-EDTA tube. Blood samples were processed within 30--60 min with an initial spin at 800 × g for 10 min at 4°C. The plasma was transferred to another tube and centrifuged at 13,000 × g for 10 min to remove the remaining blood cells. The supernatant plasma samples were then aliquoted into 2 ml/tube and either immediately processed for DNA extraction or stored at −80°C. ccfDNA was extracted from 5 ml of plasma using the QIAamp DNA Mini blood kit (Qiagen, Valencia, CA, USA) according to the 'Blood and Body Fluid Protocol'. ccfDNA samples were kept at −20°C until use.

Plasma was prospectively collected from 9 patients both pre- and post-treatment, and ccfDNA concentrations and FI values were determined using quantitative PCR as previously described ([@b25-or-37-01-0057]). Briefly, qPCR amplifications were performed in duplicate in a 20-µl PCR mix, including the amplification primer and DNA extract. Thermal cycling consisted of three repeated steps: a 3-min Hot Start polymerase activation-denaturation step at 95°C, followed by 40 repeated cycles at 95°C for 10 sec and 60°C for 30 sec. Melting curves were obtained by increasing the temperature from 55 to 90°C with a plate reading every 0.2°C. Serial dilutions of genomic DNA were used as a standard for quantification. The quantity of ccfDNA fragments of different sizes was assessed using an integrated PCR system that targeted intronic sequences within the same regions. The degree of ccfDNA FI was assessed by calculating the ratio of the concentration determined by using the primer set amplifying a large target (\>250 bp) to the concentration determined by using the primer set amplifying a short target (\<100 bp). These values were normalized, and the ratio of large fragments (\~ 250 bp) to small fragments (\<100 bp) was recorded as the DNA FI. The ratio of DNA FI values before and after treatment (pre-treatment FI/post-treatment FI) were stratified by values less than or greater than 1.

Samples for atomic-force microscopy (AFM) analysis were prepared as previously described ([@b26-or-37-01-0057]). Briefly, a 2 µl ccfDNA sample in a Tris and EDTA solution was deposited onto APS-mica. The sample was then rinsed with deionized water and dried with nitrogen gas. It was mounted on a Nanoscope IIIa AFM for imaging (Veeco/Digital Instruments, Santa Barbara, CA, USA). Images were acquired in tapping mode in air using silicon tapping mode probes. Ten images were acquired for each ccfDNA sample. Acquired AFM images were analyzed using commercially available software, FemtoScan Online (Advanced Technologies Center, Moscow, Russia), for measurements of ccfDNA fragment lengths. Measured DNA fragments were sorted by size, and the fragment size distribution was obtained by dividing the number of fragments in each bin by the total number of fragments. DNA fragment size conversions were made on the assumption that 1 bp was equivalent to a length of 0.34 nm. AFM was performed on 6 patients, 4 KRAS WT and 2 KRAS mutants.

### Follow-up and statistical analysis

A retrospective review was conducted for clinical outcomes, demographic information, and tumor mutational status. In 47 patients, interval imaging, including CT, PET-CT, and/or MRI, was available for tumor response assessment using RECIST criteria as a score of complete response, partial response, stable disease, or progressive disease ([@b27-or-37-01-0057]). Because use of ^90^Y microspheres is a liver-directed therapy, tumor response was limited to an assessment of hepatic lesions in the liver lobe or lobes treated, with whole liver local control assessed for bilobar treatments and treated liver lobe local control assessed for unilobar treatments. Tumor mutational status was available for 49 patients based on the review of documented pathology reports. Actuarial survival and progression-free survival were evaluated by the Kaplan-Meier method. Univariate analysis was performed using Kaplan-Meier, and multivariate analysis was assessed using Cox regression analysis. A two-tailed t-test was used to assess changes in fragment size with AFM in WT and KRAS mutant patients before and after single lobe ^90^Y treatment.

Results
=======

### Patient characteristics

Patient characteristics are noted in [Table I](#tI-or-37-01-0057){ref-type="table"}. Our patient population consisted of 58 patients diagnosed with colon cancer at a median age of 56 years (range, 31--85 years). Half of the patients were male, 86% had a performance status ≤1, and 67% of the patients had metastatic disease outside the liver. Patients received ^90^Y treatment for a median of 20 months (range, 5--52 months) after diagnosis with hepatic metastases. As summarized in [Table II](#tII-or-37-01-0057){ref-type="table"}, our patients received a median of two chemotherapy treatment lines prior to ^90^Y treatment, ranging from 1 to 5. Every patient had exposure to either 5-FU or capecitabine prior to treatment.

As summarized in [Table III](#tIII-or-37-01-0057){ref-type="table"}, tumor mutation information was available for 49 patients, with 27 (55%) being KRAS mutant, 21 (43%) being WT, and 1 (2%) being Her2/neu overexpressing. A larger proportion of KRAS WT patients were treated with anti-EGFR-targeted agents before ^90^Y radioembolization, but the overall exposure to EGFR inhibitors was low (10%, [Table II](#tII-or-37-01-0057){ref-type="table"}).

### ^90^Y radioembolization procedure

A total of 90 treatments were delivered to 58 patients ([Table I](#tI-or-37-01-0057){ref-type="table"}). Eight patients received treatment to the left lobe alone, 18 received treatment to the right lobe alone, and 32 received treatment to both liver lobes spaced approximately a month apart. The delivered activity during ^90^Y treatment ranged from 8.9 to 59.4 mCi.

### Imaging response and liver progression-free survival

In 47 patients, interval imaging, including CT, PET/CT and/or MRI, was available for tumor response assessment. [Fig. 1](#f1-or-37-01-0057){ref-type="fig"} shows representative CT images before ([Fig. 1A and C](#f1-or-37-01-0057){ref-type="fig"}) and after treatment ([Fig. 1B and D](#f1-or-37-01-0057){ref-type="fig"}) in a WT ([Fig. 1A and B](#f1-or-37-01-0057){ref-type="fig"}) and KRAS mutant ([Fig. 1C and D](#f1-or-37-01-0057){ref-type="fig"}) patient. The median time of imaging after the procedure was 2 months following treatment. RECIST criteria were utilized to measure the response in each liver lobe treated ([@b28-or-37-01-0057]). Imaging assessment showed a partial response in 9 patients (19%), stable disease in 20 (43%), and progressive disease in 18 (38%).

Median liver lobe progression-free survival duration after ^90^Y treatment was 2 months \[95% confidence interval (CI), 0.34--3.66 months\] for the entire cohort ([Fig. 2A](#f2-or-37-01-0057){ref-type="fig"}). The median local control duration assessed according to tumor mutation was longer in the WT vs. KRAS mutant patients of 2 vs. 1 month, respectively (p=0.088) ([Fig. 2B](#f2-or-37-01-0057){ref-type="fig"}). While this was not significant with univariate analysis, it was significant with multivariate analysis (p=0.031) ([Table IV](#tIV-or-37-01-0057){ref-type="table"}). Progression-free survival in the liver was not significantly different by univariate or multivariate analysis in patients stratified by prior treatment number of chemotherapy lines ([Table IV](#tIV-or-37-01-0057){ref-type="table"}). However, patients with prior exposure to nilotinib or sunitinib had worse progression-free survival in the liver with univariate analysis (5.6±1.3 vs. 0.5±0.5 months, p=0.034), but this was not significant with multivariate analysis ([Table V](#tV-or-37-01-0057){ref-type="table"}).

### Survival outcomes

Of the 58 patients, 46 died during follow-up. As shown in [Fig. 3A](#f3-or-37-01-0057){ref-type="fig"}, the median survival from diagnosis was 35 months (95% CI, 26.9--43.1 months). The median survival after ^90^Y was 6 months (95% CI, 4.55--7.45 months) in the entire cohort ([Fig. 3B](#f3-or-37-01-0057){ref-type="fig"}), with a 12-month survival of 33%. Patients with ECOG performance status ≤1 had significantly improved median survival over those with ECOG ≥2 (7 vs. 4 months, p=0.001) ([Fig. 3C](#f3-or-37-01-0057){ref-type="fig"} and [Table IV](#tIV-or-37-01-0057){ref-type="table"}). In addition, with univariate analysis, patients younger than 60 also had improved survival after treatment (p=0.044) ([Table IV](#tIV-or-37-01-0057){ref-type="table"}). The median survival from treatment stratified by mutational status ([Fig. 3D](#f3-or-37-01-0057){ref-type="fig"} and [Table IV](#tIV-or-37-01-0057){ref-type="table"}) was longer in the WT as compared to the KRAS mutant patients at 7 months (95% CI, 1.8--12.2) vs. 5 months (95% CI, 3.0--7.0), but did not achieve statistical significance (p=0.059). While overall survival from treatment stratified by the number of prior chemotherapy lines was not significant with either univariate or multivariate analysis ([Table IV](#tIV-or-37-01-0057){ref-type="table"}), prior exposure to oxaliplatin was associated with improved survival from treatment (22.5±1.1 vs. 9.0±1.0 months, p=0.009) and prior exposure to nilotinib/sunitinib was associated with a worse survival from treatment (10.5±1.1 vs. 3.8±0.48 months, p=0.01) ([Table V](#tV-or-37-01-0057){ref-type="table"}). Futhermore, with multivariate analysis, survival after treatment was significantly associated with performance status \[p=0.003; HR, 0.24 (CI, 0.09--0.61); [Table IV](#tIV-or-37-01-0057){ref-type="table"}\] and prior exposure to oxaliplatin and nilotinib/sunitinib (p=0.039 and p=0.045, respectively; [Table V](#tV-or-37-01-0057){ref-type="table"}).

Survival from diagnosis was improved in those patients with ECOG performance status ≤1 (42.3±4.5 vs. 27.3±6.5 months, p=0.17; [Table IV](#tIV-or-37-01-0057){ref-type="table"}). With multivariate analysis, both the performance status and the number of previous chemotherapy lines were significant for survival from cancer diagnosis ([Table IV](#tIV-or-37-01-0057){ref-type="table"}). Prior exposure to oxaliplatin was statistically significant for overall survival from diagnosis (70.5±8.8 vs. 37.4±3.8 months, p=0.039) with univariate analysis, but did not maintain significance with multivariate analysis ([Table V](#tV-or-37-01-0057){ref-type="table"}).

### ccfDNA analysis

ccfDNA, which was collected immediately prior to ^90^Y administration and 2--4 weeks after single lobe treatment, was detected in all of the 9 analyzed samples by PCR. In the WT and KRAS mutant patients, DNA FI was decreased from a median of 0.73--0.65 after treatment. As shown in [Fig. 4](#f4-or-37-01-0057){ref-type="fig"}, a decrease in the ratio of DNA FI (pre-treatment FI/post-treatment FI), or an increase in the fraction of small DNA fragments, after single lobe treatment was associated with improved outcomes. While overall survival from treatment did not meet statistical significance in patients with a DNA FI ratio pre/post-treatment of \>1 vs. \<1 ([Fig. 4A](#f4-or-37-01-0057){ref-type="fig"}, p=0.17), overall survival from diagnosis was significantly improved in those patients ([Fig. 4B](#f4-or-37-01-0057){ref-type="fig"}, p=0.04).

### AFM analysis

Analysis by AFM of paired pre- and post-treatment samples was performed in 4 WT and 2 KRAS mutant patients. An illustrative example is shown in [Fig. 5](#f5-or-37-01-0057){ref-type="fig"} of sample AFM images of WT ([Fig. 5A and B](#f5-or-37-01-0057){ref-type="fig"}) and KRAS mutant ([Fig. 5C and D](#f5-or-37-01-0057){ref-type="fig"}) DNA before ([Fig. 5A and C](#f5-or-37-01-0057){ref-type="fig"}) and after ([Fig. 5B and D](#f5-or-37-01-0057){ref-type="fig"}) single liver lobe exposure to ^90^Y. This figure demonstrates the capability of AFM in measuring individual DNA fragments and illustrates the treatment related differences in WT and KRAS mutant patient ccfDNA.

In a pooled analysis of 4 WT and 2 KRAS mutant patients, the average size of ccfDNA bp change after single lobe treatment was significantly larger in the WT patients, with the WT ccfDNA decreasing from 251.86 to 154.65 bp as compared to the KRAS mutant ccfDNA decreasing from 177.98 to 155.09 bp (p=0.013). Quantification of changes in different fragment size groups before and after treatment is shown in [Fig. 6](#f6-or-37-01-0057){ref-type="fig"}. While both WT and KRAS mutant patient ccfDNA had decreased percentage of \>250 bp size range and higher proportion of 85--350 bp ccfDNA after single lobe treatment, the magnitude of change was larger in the WT patients, with the 85--350 bp size fragments increasing by 12.3% in the WT ([Fig. 6A](#f6-or-37-01-0057){ref-type="fig"}) and 3.6% in the KRAS mutant ([Fig. 6B](#f6-or-37-01-0057){ref-type="fig"}).

Discussion
==========

In this study we demonstrated that KRAS mutant patients had less radiation-related changes in ccfDNA after treatment than WT patients and that radiation treatment changes in ccfDNA, as measured by DNA FI, were predictive for patient overall survival. While several studies have previously described the predictive potential of ccfDNA levels in overall survival after chemotherapy for metastatic CRC patients ([@b23-or-37-01-0057],[@b29-or-37-01-0057]), this is the first study to demonstrate the treatment FI ratio as a potential predictive marker for survival.

Molecular biomarker research has revealed CRC to be a heterogeneous disease with multiple molecular disease subtypes ([@b12-or-37-01-0057]). CRC biomarker research has led to the development of new chemotherapy regimens and novel monoclonal antibody therapies targeting critical molecules in cell signaling pathways, and these treatment advances have resulted in improvements in overall survival for metastatic CRC ([@b4-or-37-01-0057]). There is evidence that tumor response to chemotherapy is predictive for overall survival. In a study by Adam *et al*, response to chemotherapy correlated with improved overall survival in patients who received neoadjuvant chemotherapy prior to curative liver metastatic tumor resection ([@b30-or-37-01-0057]). Mechanisms of resistance to targeted therapies are abundant, with the majority of KRAS WT tumors not responding to anti-EGFR therapy ([@b31-or-37-01-0057]). Anti-EGFR therapy resistance has been associated with other gene mutations, epigenetic silencing, and augmented expression of other receptor tyrosine kinases, resulting in a complex tumor microenvironment that may be difficult to predict treatment response ([@b12-or-37-01-0057]).

Multiple clinical trials have confirmed the lack of clinical benefit of anti-EGFR therapy against RAS mutant tumors ([@b32-or-37-01-0057],[@b33-or-37-01-0057]). The meta-analysis from Sorich *et al* in 2015 demonstrated that tumors without RAS mutations exhibited an improved clinical response compared to RAS mutant tumors, regardless of the specific targeted therapies or partner chemotherapy used ([@b34-or-37-01-0057]). In addition, KRAS mutant tumors have been associated with poor survival outcomes and treatment responses in the absence of targeted agents ([@b16-or-37-01-0057],[@b35-or-37-01-0057],[@b36-or-37-01-0057]), which may indicate that these tumors are less responsive to systemic therapies. The impact of KRAS mutation status on radiation treatment response is less clear, but is an area of investigation. Lahti *et al* reported KRAS mutation status to be predictive for overall survival after ^90^Y radioembolization for unresectable CRC liver metastases ([@b18-or-37-01-0057]). While overall survival after ^90^Y treatment in KRAS mutant vs. WT patients did not quite meet statistical significance in our study, there was a clear separation in the curves. Notably, mutation status was significant on multivariate analysis for liver progression-free survival in our study. Intriguingly, it is possible that the same differential chemotherapy responses of WT and KRAS mutant tumors that have been well described are also true for radiation treatment.

El Messaoudi *et al* recently demonstrated that higher ccfDNA concentrations, higher levels of mutant ccfDNA, and the level of ccfDNA fragmentation correlated with shorter overall survival in metastatic CRC patients ([@b22-or-37-01-0057]). While there was no difference in overall survival from treatment as a function of DNA integrity index in our study, analysis of survival from diagnosis was statistically longer in those patients with a decrease in their fragment ccfDNA size after treatment. The discrepancy in survival may be a function of the small number of patients in our study. However, it may also be a function of the limitations of ^90^Y in treating metastatic CRC, which have been previously outlined in the recently published SIRFLOX study ([@b11-or-37-01-0057]), with the overall aim of ^90^Y treatment being to control liver disease and not to control systemic burden. Radiation treatment-related DNA FI changes are likely reflective of tumor response capability. Indeed, DNA FI may reflect tumoricidal changes and could serve as a biomarker to assess treatment response.

Our study sample with molecular data is small. While our findings are hypothesis driving, definitive conclusions are limited until a more robust analysis can be performed on a larger number of patients. In addition, while all of our patients received chemotherapy prior to ^90^Y treatment and many were considered chemotherapy refractory, our patient population was diverse in their overall level of health and in the natural history of their disease. It is not surprising that overall survival was improved in patients with better performance statuses. While no overall survival differences were observed among patients with or without extrahepatic disease, the overall survival differences seen based on the number and types of chemotherapy exposures likely reveals variation in patient performance status and disease course. Further molecular studies on a larger group of patients are necessary to validate our observational findings.

In conclusion, ^90^Y radioembolization is an effective treatment for CRCLM in extending local control for liver dominant metastatic disease. However, KRAS mutant tumors may be more radio-resistant to treatment. In this study, changes in ccfDNA FI were correlated with overall survival, likely indicating that these changes are reflective of treatment response. Measurements of FI may have the potential to be another molecular biomarker that could predict treatment response to therapy.

![Representative CT images of DNA in (A and B) wild-type and (C and D) KRAS mutant patients before (A and C) and after (B and D) ^90^Y treatment.](OR-37-01-0057-g00){#f1-or-37-01-0057}

![Progression-free survival in the liver: (A) all patients; (B) patients by mutational status.](OR-37-01-0057-g01){#f2-or-37-01-0057}

![Overall survival: (A) all patients from diagnosis; (B) overall survival from treatment all patients; (C) overall survival of patients by performance status from treatment; (D) overall survival of patients by mutation status from treatment.](OR-37-01-0057-g02){#f3-or-37-01-0057}

![Evaluation of KRAS mutant and wild-type patients for changes in circulating cell-free DNA. (A) Overall survival from treatment according to DNA fragmentation index (FI) changes; (B) overall survival from diagnosis according to DNA FI changes.](OR-37-01-0057-g03){#f4-or-37-01-0057}

![Representative atomic-force microscopy images of DNA in (A and B) wild-type (WT) and (C and D) KRAS mutant patients before (A and C) and after (B and D) yttrium-90 (^90^Y) treatment. ^90^Y treatment appeared to induce significant fragmentation in circulating cell-free DNA for KRAS WT but not in KRAS mutant patients.](OR-37-01-0057-g04){#f5-or-37-01-0057}

![Comparison of the fractional fragment size distribution of circulating cell-free DNA (ccfDNA) from (A) wild-type (WT) and (B) KRAS mutant samples before and after single lobe treatment with yttrium-90 (^90^Y). The estimated amount of each ccfDNA fraction expressed as the percentage of the total ccfDNA estimated as the sum of the ccfDNA amount of the three size fractions in (A) WT and (B) KRAS mutant patients before (blue) and after (red) treatment in (A) four pooled WT samples and (B) two pooled KRAS mutant samples.](OR-37-01-0057-g05){#f6-or-37-01-0057}

###### 

Patient characteristics, n=58.

  Patient characteristics            n (%)
  ---------------------------------- -------------
  Age at ^90^Y treatment (years)     
    Median (range)                   56 (31--85)
    ≤40                              3 (5)
    \>40 to ≤50                      13 (22)
    \>50 to ≤60                      16 (28)
    \>60 to ≤70                      16 (28)
    \>70                             10 (17)
  Race                               
    White                            36 (62)
    Black                            12 (21)
    Other                            10 (17)
  Gender                             
    Male                             29 (50)
    Female                           29 (50)
  Performance status (ECOG)          
    0                                14 (24)
    1                                36 (62)
    ≥2                               7 (12)
    Unknown                          1 (2)
  Location of lesion treated         
    Right lobe                       50 (86)
    Left lobe                        40 (69)
    Both lobes                       32 (55)
  Presence of extrahepatic disease   
    Absent                           19 (33)
    Present                          39 (67)

^90^Y, yttrium-90.

###### 

Chemotherapy characteristics, n=58.

  Chemotherapy characteristics                                              n (%)
  ------------------------------------------------------------------------- ----------
  No. of previous chemotherapy lines                                        
    1                                                                       12 (21)
    2                                                                       29 (50)
    ≥3                                                                      17 (29)
  Exposure to 5-fluoruracil or capecitabine                                 
    No                                                                      0 (0)
    Yes                                                                     58 (100)
  Exposure to leucovorin                                                    
    No                                                                      9 (16)
    Yes                                                                     49 (84)
  Exposure to oxaliplatin                                                   
    No                                                                      5 (9)
    Yes                                                                     53 (91)
  Exposure to irinotecan                                                    
    No                                                                      27 (47)
    Yes                                                                     31 (53)
  Exposure to bevacizumab                                                   
    No                                                                      14 (24)
    Yes                                                                     44 (76)
  Exposure to cetuximab or panitumumab                                      
    No                                                                      52 (90)
    Yes                                                                     6 (10)
  Exposure to nilotinib or sunitinib                                        
    No                                                                      54 (93)
    Yes                                                                     4 (7)
  Exposure to other agents^[a](#tfn2-or-37-01-0057){ref-type="table-fn"}^   
    No                                                                      44 (76)
    Yes                                                                     14 (24)

Includes PARP inhibitors, anti-PDL1, docetaxel, C-met inhibitors, and tezacitabine.

###### 

Mutation status, n=49.

  Mutation status   n (%)     Median age (years)
  ----------------- --------- --------------------
  KRAS WT           21 (43)   53
  KRAS mutated      27 (55)   60
  Her2/neu          1 (2)     38

WT, wild-type.

###### 

Univariate and multivariate analyses for progression-free survival and overall survival.

                                                    Progression-free survival in liver   Overall survival treatment   Overall survival diagnosis                                                                    
  ------------------------------------ ------------ ------------------------------------ ---------------------------- ---------------------------- ------- -------------------- ------- ------- ------------------- -------
  Age (years)                          \<60         0.230                                2.12 (0.41--10.99)           0.370                        0.044   0.82 (0.22--3.09)    0.766   0.598   1.92 (0.47--7.95)   0.366
  Gender                               Female       0.065                                1.55 (0.60--3.98)            0.364                        0.442   0.87 (0.38--1.98)    0.739   0.458   0.82 (0.34--1.94)   0.644
  Performance status                   ≤1 vs. ≥2    0.395                                0.63 (0.13--3.08)            0.568                        0.001   0.24 (0.09--0.61)    0.003   0.017   0.21 (0.07--0.62)   0.005
  Smoking                              No           0.742                                1.24 (0.36--4.27)            0.731                        0.444   1.38 (0.51--3.76)    0.524   0.013   2.03 (0.62--6.68)   0.245
  Presence of extrahepatic disease     No           0.445                                0.83 (0.30--2.30)            0.723                        0.775   0.90 (0.40--2.01)    0.801   0.722   1.36 (0.58--3.18)   0.475
  Mutation status                      KRAS WT      0.088                                0.29 (0.09--0.90)            0.031                        0.059   0.58 (0.26--1.33)    0.200   0.322   0.69 (0.28--1.74)   0.435
  FI                                   \<1          0.716                                NA                                                        0.170   NA                           0.040   NA                  
  No. of previous chemotherapy lines   Continuous                                        3.87 (0.47--32.16)           0.211                                1.11 (0.17--7.18)    0.911           0.2 (0.05-.89)      0.035
                                       1 vs. ≥2     0.387                                2.96 (0.23--38.73)           0.409                        0.652   1.60 (0.19--13.59)   0.667   0.278   0.21 (0.03--1.47)   0.115
                                       ≤2 vs. ≥3    0.703                                5.07 (0.35--73.60)           0.235                        0.845   1.00 (0.11--9.28)    0.998   0.801   0.24 (0.04--1.50)   0.128

FI, fragmentation index; WT, wild-type; NA, not applicable.

###### 

Univariate and multivariate analyses for progression-free survival and overall survival with chemotherapy exposure.

                           Progression-free survival in liver   Overall survival treatment   Overall survival diagnosis                                                                    
  ------------------------ ------------------------------------ ---------------------------- ---------------------------- ------- ------------------- ------- ------- -------------------- -------
  Oxaliplatin              0.5                                  0.61 (0.19--2.0)             0.413                        0.009   0.12 (0.02--0.90)   0.039   0.039   0.174 (0.02--1.33)   0.092
  Leucovorin               0.464                                1.35 (0.51--3.55)            0.545                        0.063   1.89 (0.84--4.28)   0.127   0.391   0.94 (0.41--2.15)    0.886
  Irinotecan               0.514                                0.79 (0.34--1.81)            0.569                        0.689   0.71 (0.38--1.34)   0.291   0.114   1.28 (0.64--2.56)    0.479
  Bevacizumab              0.073                                0.39 (0.12--1.32)            0.132                        0.426   1.36 (0.68--2.75)   0.385   0.858   1.0 (0.50--2.0)      0.988
  Cetuximab or panitumab   0.799                                0.56 (0.17--1.84)            0.338                        0.708   1.34 (0.46--3.87)   0.59    0.332   1.65 (0.55--4.93)    0.372
  Nilotinib or sunitinib   0.034                                0.45 (0.15--1.34)            0.15                         0.01    0.32 (0.11--0.97)   0.045   0.1     0.47 (0.16--1.41)    0.176
